Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
TB-500 is a lab-made peptide of seven amino acids, copied from a short stretch of the natural protein thymosin beta-4, and it is promoted online for tendon, muscle and ligament injuries and wound repair, among other uses. The strongest evidence for TB-500 itself comes from animal studies: in one 2026 study, repaired Achilles tendons withstood more force in rats given a peptide described as TB-500. In people, no trial of TB-500 has reported results; the published record is three patients who received it mixed with four other drugs, and the human trials usually quoted for it tested thymosin beta-4, a different and much larger molecule.
This review keeps the two molecules apart: for every study, it says which one was used. It is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval.
- Evidence in people
- TB-500: one report of three patients and no trial results. Trials often cited tested thymosin beta-4, a different molecule.
- The claim you’ve heard
- Speeds injury recovery: not tested in people; one rat study. Safety in people is untested too.
- Doses tested in people
- None by injection under the skin or into muscle. The trial doses below are for thymosin beta-4.
- Sport
- Prohibited at all times by WADA, which names TB-500 on its 2026 and 2027 Lists.
What TB-500 is
TB-500 is a chain of seven amino acids, numbers 17 to 23 of thymosin beta-4’s 43, written Ac-LKKTETQ, with a small chemical cap (an acetyl group) on one end.
Thymosin beta-4 is a natural protein of 43 amino acids, first isolated from calf thymus and later found in many cell types and in blood, tears and wound fluid. Inside cells it binds actin, the protein cells use to build their internal framework.
The name is not an official one: the FDA calls TB-500 “a common name and not a United States Adopted Name” and says it has found different substances “sold commercially under the same common name”. A veterinary product of that name was marketed for horse and greyhound racing from 2011.
Three substances appear in the research, and results from one are often credited to another.
| Substance | What it is |
|---|---|
| TB-500 | Seven amino acids from thymosin beta-4 with an acetyl group added. Molecular weight 889.01, or 949.1 as the acetate salt, the form HHS’s draft policy names |
| The same seven amino acids without the acetyl group (LKKTETQ) | A separate substance, used in some of the animal and cell studies quoted for TB-500 |
| Thymosin beta-4 | The natural 43-amino-acid protein, molecular weight about 4,963. Studied in randomized trials as eye drops, a skin gel and an intravenous drug |
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: TB-500 is not an FDA-approved medicine; the FDA’s staff recommended against adding it to the list of ingredients that can be used in compounding under section 503A, the federal law on pharmacy compounding. HHS, the federal department the FDA belongs to, has said in a draft policy that it does not intend to act against a pharmacy or physician that compounds TB-500 acetate alone, as an injection under the skin or into muscle, under the policy’s conditions; that is not approval.
As of November 19, 2026, TB-500 is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient TB-500 acetate as a subcutaneous or intramuscular injection for a patient-specific prescription when the policy’s conditions are met; HHS’s notice says the policy “is not binding on HHS or the public”, and it is not FDA approval.
The FDA’s own review
In a briefing document dated May 15, 2026, the FDA’s staff assessed TB-500 for wound healing and concluded that the record, including a “lack of any evidence of effectiveness”, weighed against adding either form of it to that list. Its public page on compounding safety risks says: “FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.”
The advisory committee
HHS’s policy document records that “CDER recommended against listing either form, and the PCAC voted in favor of both forms” (CDER is the FDA’s drug center; the PCAC, its compounding advisory committee, met in July 2026). An advisory vote is not approval, and the FDA has published no minutes or vote count.
HHS’s draft policy
HHS’s stated reasons for including TB-500 are that manufacturers’ certificates now supply test results the FDA’s staff had found missing, that “historical use is now documented and quantified”, and that “the safety concerns CDER identified are inferential rather than observed, the parent protein has a controlled human safety record across several routes, and the fragment is rapidly truncated in human serum” (cut shorter in blood). HHS gives no source for the serum statement or the historical-use data. Its statement applies only when all of the policy’s conditions are met, including these:
- The ingredient is TB-500 acetate, compounded as an injection under the skin or into muscle. The policy does not name full-length thymosin beta-4, or an oral or nasal form of TB-500.
- “The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A” (the policy’s list of six peptides). A compounded injection that combines TB-500 with BPC-157 falls outside the policy.
- The ingredient has a certificate of analysis from an FDA-registered manufacturer.
The policy does not change section 503A, and HHS says it “may revisit” the policy “if, among other things, a safety signal or product quality issue arises”.
Warning letters
In June 2023 the FDA warned an online seller of injectable and nasal-spray TB-500 that its products were unapproved “new drugs”.
Sport
WADA’s 2026 and 2027 Prohibited Lists name “Thymosin-β4 and its derivatives e.g. TB-500” in class S2.3, prohibited at all times.
Claims you’ll see, and why sources disagree
Pages about TB-500 reach different conclusions from the same small record, for three reasons.
- Two molecules, one name. Many pages call TB-500 a synthetic version of thymosin beta-4 and credit it with that protein’s human trials. The FDA says the two “are not the same substance”.
- Animal and lab results read as results in people. The mouse wound study behind TB-500’s nomination to the FDA tested the peptide without its acetyl group, whose effects, the FDA says, “cannot be directly extrapolated to the N-acetylated heptapeptide TB-500”.
- Trials quoted by their best line. No randomized trial of thymosin beta-4 has met a main effectiveness goal. The SEER-1 eye trial’s report is titled as showing that the drops promote healing; its text says the main goal “was not met with statistical significance” (p = 0.0656).
“Not tested in people” is not the same as “doesn’t work”. It cuts both ways: TB-500 has not been shown to help, and it has not been shown to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| TB-500 is a synthetic version of thymosin beta-4 | Chemistry | Not accurate: it is 7 of the protein’s 43 amino acids, with an acetyl group added |
| It speeds recovery from tendon, muscle and ligament injuries | Animal studies: one rat study | Not tested in people |
| It speeds wound healing | Lab and animal studies, mostly of other molecules | Not tested in people. In the one cell test of TB-500 itself, it did not significantly close the wound |
| It grows new blood vessels | Lab studies of thymosin beta-4 and its seven-amino-acid sequence | Not tested in people. The same property is behind the tumour concern |
| It reduces inflammation or scarring | Animal and lab studies, mostly of thymosin beta-4 and related peptides | Not tested in people. No study measured scarring |
| It protects the heart after a heart attack | Tested in people, for thymosin beta-4 only | A 96-patient trial missed its main goal. No TB-500 trial has results |
| It works best “stacked” with BPC-157 | Theory; one rat study | Not tested in people. In rats, the two together were no better than either alone |
| It is safe or well tolerated | One report of three patients; no safety study | Not established. No safety study in people or animals; the one published report lists no adverse events over four weeks |
What the evidence consists of
The evidence is set out by level, the strongest first.
Tested in people: TB-500
No trial of TB-500 in people has reported results. The FDA searched the medical literature and wrote: “no articles were found in which TB-500 was administered to humans.” One trial is registered as recruiting (NCT07487363): a placebo comparison sponsored by Hudson Biotech (industry), planned for 80 adults with stable cardiovascular disease, with adverse events as its main outcomes, due to finish in February 2028. The registration doesn’t disclose the doses or the route and contradicts itself on blinding, so we read it with caution.
Tested in people: thymosin beta-4, not TB-500
These are the trials usually quoted for TB-500. All tested the full 43-amino-acid protein; doses are in the dosing section.
| Trials | People | What was given | What happened | Funding and limits |
|---|---|---|---|---|
| Dry eye, phase 3: ARISE-2 and ARISE-3 | 601 and 700 | Eye drops or placebo | Each missed both main goals | ReGenTree (industry) |
| Dry eye, phase 2: two trials, 2015 | 72 and 9 | Eye drops or drug-free drops | The larger missed both main goals; some secondary measures favoured the drops. The smaller reported 35.1% less discomfort and 59.1% less corneal staining than control | A RegeneRx product. Larger: registry sponsor now ReGenTree; authors report no conflicts. Smaller: an investigator-site study |
| SEER-1, a poorly healing cornea (neurotrophic keratopathy), phase 3 | 18 | Eye drops or placebo | Healed: 6 of 10 vs 1 of 8 (p = 0.0656). Main goal not met | Stopped at 18 of 46 planned. ReGenTree; three authors worked for it or its parent company |
| SEER-2, the same condition, phase 3 | 70 | Eye drops or placebo | No results posted | ReGenTree |
| Phase 2 skin-gel trials: venous ulcers, pressure ulcers, epidermolysis bullosa | 72, 72 and 30 | Skin gel or drug-free gel | Healed: 12 of 55 vs 4 of 17; 8 of 54 vs 3 of 18; 8 of 22 vs 5 of 8. Only the third was tested statistically: no significant difference | Main goal was safety. RegeneRx; one with sigma-tau, one with FDA orphan-product funding. In the second, 21 of 72 did not complete; the third stopped at 30 of 36 planned |
| Healthy volunteers: Ruff 2010, Wang 2021 | 40 and 84 | By vein, or placebo | No serious adverse events or dose-limiting toxicity in either | Safety studies. Ruff: funding not stated in the abstract. Wang: Beijing Northland Biotechnology; three authors are its employees |
| Heart attack, phase 2: Zhang 2025 | 96 (the registry lists 90) | By vein, or placebo | Main goal not met. A subgroup treated within 8 hours (43 people) had less heart-muscle damage at one dose (P = 0.016), in an analysis chosen afterwards | Sponsored by the same company (“Beijing Northland Biotech Co. Ltd” in the paper), with Chinese academic funds; three authors are its employees. A second trial, of 62 people, was completed in 2021 and has posted no results |
In randomized trials enrolling about 1,900 people, thymosin beta-4’s side effects occurred at rates close to placebo’s. No randomized trial has shown a statistically significant benefit on its main measure of effectiveness; the favourable results are secondary measures, a subgroup analysed afterwards, and small studies. For SEER-1, a 2025 Cochrane review gives a risk ratio for healing of 9.00 (95% interval 0.57 to 141.88), which is compatible with a large benefit, none, or placebo doing better, and rates the evidence low-certainty.
Outside the randomized trials, a 2026 pilot (Majumdar and colleagues) gave five adults with a spinal cord injury weekly injections under the skin of BPC-157 and of a product its article calls thymosin beta-4, which it describes as a 43-amino-acid peptide; five others had rehabilitation alone. It was not randomized or blinded, the trial registration it cites could not be found, the product’s identity is unverified, and it is not a study of TB-500, a name its article never uses.
Reported in people: TB-500
| Report | People | What was given | What happened | Limits |
|---|---|---|---|---|
| Froum and colleagues 2026 | 3 patients with numbness after a jaw nerve injury | TB-500 injected locally under the lining of the mouth weekly for 4 weeks, in one syringe with ARA-290, BPC-157, a steroid and a local anaesthetic | All three improved. Adverse events: “None reported” | No control group; the authors say “causality cannot be established” and that the course may be “the expected natural history of recovery”. They declare no commercial relationships; one is affiliated with the American Academy of Anti-Aging Medicine |
Animal studies
Two animal studies tested a peptide their abstracts call TB-500. Neither abstract says whether it carried the acetyl group, and we read only the abstracts.
- Rat tendon repair (Biçer and colleagues, 2026). Thirty-two rats (eight per group) had an Achilles tendon cut and repaired, then received daily TB-500 (injected into the abdomen), BPC-157, both or neither for four weeks. Tendons withstood a higher load in both single-peptide groups, “reaching statistical significance in the TB-500 group (p < 0.05)”. The combination “did not confer additional benefits compared to either agent alone”, and the authors call the study “exploratory”.
- Mouse model of Alzheimer’s disease (Ou and colleagues, 2026). TB500 and a second thymosin beta-4 fragment improved performance on memory tests; the amyloid deposits “remained unchanged”.
In a 2003 study often cited for TB-500 (Philp and colleagues), thymosin beta-4 or the peptide without its acetyl group was applied to small skin wounds in aged mice; tissue examined on day 7 “suggested” greater closure and more collagen, and the FDA notes that the study “lacks an assessment of the dose-response relationship”.
Thymosin beta-4’s large animal and lab literature is dominated by one network of investigators (Kleinman, Goldstein, Sosne and colleagues), often with RegeneRx, which funded several of the trials above; the same authors wrote the main reviews. That concentration is a reason for caution in itself.
Lab studies and how it is thought to work
The FDA states the proposed mechanism as a hypothesis: “It has been hypothesized that, by binding to globular G-actin but not filamentous F-actin, LKKTETQ may have the same G-actin buffering capacity of thymosin β4” (G-actin is the unassembled form of actin). In plain terms: thymosin beta-4 holds a reserve of actin building blocks inside cells (lab studies), TB-500’s sequence includes the part that binds actin (lab studies), and so the fragment might help cells move into damaged tissue and form new vessels (theory).
- Blood-vessel growth (lab studies of thymosin beta-4 and its seven-amino-acid sequence). In human vessel-lining cells and chick tissue, the two “display near-identical activity at ~50 nM” (Philp and colleagues, 2003).
- TB-500 itself (lab study). A Korean anti-doping laboratory scratched a gap in a layer of connective-tissue cells and added TB-500 at one concentration (Rahaman and colleagues, 2024). It did not significantly close the gap; one breakdown product, Ac-LKKTE, “caused a small, but significant wound closure”, and the authors suggest that the activity reported for TB-500 “may be due to its metabolite Ac-LKKTE rather than the parent form”.
None of this has been demonstrated in people, for either molecule, and the stronger-looking results can’t be assumed to carry over to TB-500 injected under the skin: they come from a different molecule given in other ways, from the peptide without its acetyl group, or from one exploratory rat study.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No published study has compared doses of TB-500 in people, so none can be called optimal.
Doses tested in people
TB-500. One published report (Froum and colleagues, 2026) gave three patients 10 mg, mixed with four other drugs, injected locally under the lining of the mouth, weekly for 4 weeks. No published study has given TB-500 to people by injection under the skin or into muscle, the two forms named in HHS’s draft policy, or by mouth or nasal spray.
Thymosin beta-4. These doses, sometimes quoted online as TB-500’s, belong to a different, much larger molecule.
| Study | People | Dose | Route | How often and how long |
|---|---|---|---|---|
| Ruff and colleagues 2010 | 40 healthy volunteers | 42, 140, 420 or 1,260 mg | Into a vein | Once, then daily for 14 days |
| Wang and colleagues 2021 | 84 healthy volunteers | 0.05 to 25 µg/kg once; 0.5, 2.0 or 5.0 µg/kg repeated | Into a vein | Once, or daily for 10 days |
| Zhang and colleagues 2025; NCT05485818 (no results posted) | 96 and 62 after a heart attack | 0.5 or 1 µg/kg; 0.25, 0.5 or 2.0 µg/kg | Into a vein | Daily for 7 days |
| Three skin-gel trials | 72, 72 and 30 | 0.01% to 0.1% gel, three strengths in each | On the skin | Daily for up to 84 days (56 in one) |
| Six dry-eye and corneal trials | 9 to 700 each | 0.1% solution | Eye drops | 2 to 6 times a day for 14 to 28 days |
| Majumdar and colleagues 2026, a pilot | 5 adults | 1.65 mg, beside BPC-157 0.8 mg; product identity unverified | Under the skin | Weekly for 26 weeks |
Doses in common use
These are amounts in circulation: practice that no trial set, reported so that you can see where they come from and how they compare with what was studied. None has a human study behind it. “Loading” and “maintenance” are the pages’ words.
- 2 to 2.5 mg under the skin twice a week for 4 to 6 weeks (“loading”), then once a week (“maintenance”): the dominant figure, on a protocol site, a page that cites it, a telehealth seller’s article and a clinic’s dosage guide.
- 2.5 mg under the skin once or twice a week: a telehealth prescribing service (twice a week), and a compounding pharmacy’s product page that adds “No dose of this product has been established as safe or effective in humans.”
- Up to 5 mg twice a week, weekly totals of 4 to 8 mg, or “1 mg to 20 mg per week”: telehealth and clinic pages, a protocol page and, for the last (under the skin or into muscle), a seller’s page the FDA quoted in a warning letter. The published 10 mg a week was given another way, so a match is a coincidence of numbers, not support; the last range runs to twice it.
- 500 to 1,000 micrograms a day, alone or with BPC-157: a “research use only” seller, a protocol page and a telehealth prescribing service. No human study gave TB-500 daily.
- A median of 500 micrograms per injection (middle half: 350 to 2,000): what forum users report, in a 2026 preprint that is not peer-reviewed.
What the pharmacology supports, and what it doesn’t
- Amount. Convention: every amount in common use; no study we found measures how TB-500’s effect changes with dose. Inferred: if the active molecule is a breakdown product, as the 2024 cell study suggests, reasoning from the dose of TB-500 itself has no footing.
- Frequency. Measured in horses: after 10 mg under the skin, blood levels peaked at 60 to 120 minutes and were too low to measure by 6 to 10 hours (Ho and colleagues, 2012). Measured in the lab: in human serum and in human liver and kidney preparations, two laboratories found TB-500 cut down from one end into shorter pieces over hours (Zvereva and colleagues, 2016; Rahaman and colleagues, 2024). That is not a half-life measured in people. Inferred: these facts fit brief exposure after an injection, but they don’t support any particular gap between doses in people.
- Route and duration. Not measured: anything in people, and injection into muscle in any species. Convention: every course length in use; the published report’s was four weekly doses, by another route.
- Monitoring. Inferred: no blood test exists to guide a dose.
What nobody knows: what dose of TB-500, if any, is useful in people, how often, or for how long, so any schedule in use is empirical.
What common protocols get wrong
- Thymosin beta-4’s studies cited for TB-500. A telehealth seller’s “Standard loading protocol” cites two studies, both of thymosin beta-4, in rats (1999) and in mice and cultured cells (2004); a protocol page’s seven references are all thymosin beta-4 papers by title. The FDA found the same in the nomination: “three references are studies on Thymosin β4.”
- Sources misreported. A protocol site that keeps the two molecules apart still gives a gel trial’s strengths as “0.0001-0.03%” (the registry: 0.01% to 0.1%) and reports SEER-1’s healing without saying the difference was not statistically significant. Two sellers call TB-500 thymosin beta-4’s “N-terminal” fragment; it is amino acids 17 to 23.
- Figures with no human origin. One page cites another, which calls the dominant figure “community-derived”. A blog says it calculated its figure from “the recommended dosage of TB-500 for greyhounds”. On the seller’s page the FDA quoted, one dosing sentence stands under both BPC-157 and TB-500.
- A half-life stated as fact. Pages give TB-500 a half-life of “approximately 3-4 hours”, “2-3 days” or, “in rodent studies”, “1.5–3 hours”, none with a source; we found none measured in people or in rodents. One schedule is explained by a short half-life on one page and a long one on another.
- Untested schedules, combinations and routes. Cycles of 8 to 16 weeks, rest periods of 4 to 12, daily injection with BPC-157, injection into a vein, nasal sprays, capsules: no human study of TB-500 tested any of them. One page concedes: “There is no human data validating any specific rest period.” On one seller’s page “loading” is the smaller amount (“2 mg per week”) and “maintenance” the larger (“2–5 mg per week”).
The dose of a prescribed medicine is the prescriber’s decision for one patient.
Safety, and who should be most cautious
In people. No safety dataset exists for TB-500. The FDA’s search of its adverse-event database through March 26, 2025 found no reports, and it found no published case reports. That is not reassurance: as the FDA notes, “Reporting is voluntary”. The FDA’s briefing on BPC-157 (search through December 4, 2025) describes one later report: a woman injecting a “research purposes only” product containing BPC-157 and TB-500 had skin and gum darkening, which recurred when she restarted it. The FDA judged the events “likely due to the drug product” but could not assess BPC-157’s part; the report’s public record names only BPC-157, and one report does not establish cause. The one published report lists adverse events as “None reported”, in three patients over four weeks.
The FDA’s concerns. The FDA’s staff wrote that TB-500 “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities” (an immune reaction to the drug, made more likely when peptide molecules clump together), with consequences that “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions”. The FDA describes this as a risk it “cannot rule out”. It has not been observed with TB-500, and no study in people has looked for it.
Animal safety studies. None: the FDA found no single-dose, repeat-dose, genetic-damage, reproductive or cancer studies of TB-500.
Theoretical risks. On theory alone, the people with most reason for caution are those with a current or past cancer, and those with an eye disease in which new blood vessels grow (no human evidence either way).
Tumour growth or spread. A peptide thought to promote cell movement and vessel growth could, in theory, help an existing tumour. The basis is work on thymosin beta-4: mouse melanoma cells engineered to overproduce it formed larger tumours and more lung nodules (Cha and colleagues, 2003), and in ovarian cancer cells, thymosin beta-4 and three of its fragments, none of them TB-500, increased migration and invasion (Yoon and colleagues, 2021). The evidence is two-sided (a multiple myeloma study’s title reports “tumor suppressive effects”), and no cancer in a person has been attributed to either molecule in any source we found.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy or breastfeeding | No data for either molecule. No animal reproductive studies of TB-500 | FDA briefing. The registered TB-500 trial excludes both |
| Under 18 | No data | No study found |
| Current or past cancer, or cancer treatment | No human data. In theory, a risk of helping a tumour grow or spread | Mouse and cell studies of thymosin beta-4. The registered trial excludes recent cancer needing treatment |
| Other medicines | No interaction study for either molecule. In theory, cancer drugs that block blood-vessel growth work the opposite way | No study found; theory |
| Serious heart, kidney or liver disease, or immune-suppressing treatment | Not studied | Excluded from the registered trial |
| Athletes subject to drug testing | Prohibited at all times | WADA’s 2026 and 2027 Lists, class S2.3 |
Product quality
“Research use only” products carry labels such as “Not for human consumption”. For anything injected, the FDA notes, “critical quality attributes (CQAs) including sterility, bacterial endotoxins test (BET) and foreign particulates are critical safety factors” (endotoxins are toxins from bacteria).
What certificates show. The FDA looked at the certificate of analysis publicly available for TB-500 free base and found that “assay, impurities, bacterial endotoxins, and aggregates are not tested or controlled” (assay is the amount of ingredient present). For the acetate, the form HHS’s policy names, the certificate sent with the nomination set limits on impurities but gave no “Identification, Assay, Aggregates, and Bacterial Endotoxin levels”. HHS says manufacturers’ certificates now supply such results.
Independent testing. A French horse-racing laboratory analysed three products sold online as TB500, TB1000 and SGF1000 and reported that “the content of TB500/TB1000 products is not systematically consistent with it’s former descriptions” (Delcourt and colleagues, 2023). We read the abstract only, which gives no counts or measured contents.
Compounded products. The FDA’s recall database lists six recalls since 2018 of compounded injections labelled as thymosin beta-4 or thymosin beta-500: four for lack of sterility assurance and two, in October 2026, for “Lack of Processing Controls”. The recalled vials carried names such as “THYMOSIN BETA-500” and “Thymosin Beta-4 (TB4) for Injection”, so the confusion between the two molecules reaches the label.
What we make of it
This section is our judgment, not a finding.
On the evidence, TB-500 is unproven and experimental. The idea behind it is plausible: thymosin beta-4 is part of how cells move and is found in wound fluid, short pieces of it are active in lab tests, and one rat study of tendon repair favoured a peptide described as TB-500.
Almost none of that has been checked in people. Most of what is said about TB-500 is borrowed from thymosin beta-4, which has not itself met a main effectiveness goal in randomized trials. No dose of TB-500 has been tested under the skin or into muscle, and there is no safety study in people or animals.
None of this shows that TB-500 does nothing; thin evidence is not evidence of no effect. For it to earn a place in care, three things would have to be true: that it, or a breakdown product, reaches injured tissue in people in active amounts; that what related molecules do in animals carries over; and that it does so without the immune reactions the FDA is concerned about or the tumour risk theory raises. Each needs a study in people; a first safety trial is registered as recruiting.
Until those studies report, anyone considering TB-500 is weighing an unknown benefit against an unknown risk. Whether it has a place in anyone’s care, and if so for whom, after what, with what monitoring and when to stop, are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
At RCW, peptide care starts with lab tests and a visit. One of our providers then decides whether any peptide suits you, and which one; you don’t choose from a menu. Our peptide therapy page explains the process and gives the cost of Peptide Care.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- The first trial of TB-500 itself (NCT07487363), a safety trial due to finish in February 2028.
- Thymosin beta-4 results not yet posted: SEER-2 and the 62-patient heart-attack trial.
- Federal decisions. HHS’s policy is a draft; its text looks ahead to a “final rule” on whether each peptide is on the 503A list.
Common questions
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a lab-made piece of thymosin beta-4: 7 of its 43 amino acids, with an acetyl group added. The human trials quoted for TB-500 tested thymosin beta-4.
Does TB-500 work for tendon or muscle injuries?
It has not been tested in people for any injury. The evidence is one 2026 rat study (an animal study) of a peptide described as TB-500, in which repaired tendons withstood more force. Not tested doesn’t mean it can’t work; it means nobody knows.
Is TB-500 safe?
Nobody knows. The FDA’s review of TB-500 found no human safety data and no animal safety studies. Thymosin beta-4’s trial record belongs to a different molecule. The FDA’s concerns are immune reactions and impurities; a tumour risk is theory, drawn from mouse and cell studies.
Can a doctor prescribe TB-500?
TB-500 is not FDA-approved, so any prescription for it is for a compounded medicine, written for one patient. HHS’s draft policy on compounding it, with its conditions, is set out in the FDA section above; it is not FDA approval.
Is TB-500 better combined with BPC-157?
Nobody knows: no study in people has compared the combination with either peptide alone. In the one animal comparison, a 2026 rat study, the two together were no better than either alone.
Sources
Show all 45 sourcesHide sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. US Food and Drug Administration, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 2026.
- Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. US Food and Drug Administration, 2026.
- Warning Letter: Warrior Labz SARMS, CMS #655280. US Food and Drug Administration, 2023.
- openFDA drug enforcement (recall) database. US Food and Drug Administration, 2026.
- The World Anti-Doping Code International Standard Prohibited List 2026. World Anti-Doping Agency, 2025.
- UniProtKB P62328 (TYB4_HUMAN), Thymosin beta-4. UniProt Consortium, 2026.
- Case Report: Regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health, 2026.
- NCT07487363: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease. ClinicalTrials.gov, 2026.
- NCT03937882: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3. ClinicalTrials.gov, 2026.
- NCT02974907: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2. ClinicalTrials.gov, 2026.
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical Ophthalmology, 2015.
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea, 2015.
- NCT02600429: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1. ClinicalTrials.gov, 2026.
- 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences, 2022.
- NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2. ClinicalTrials.gov, 2026.
- The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 2010.
- NCT00832091: Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers. ClinicalTrials.gov, 2026.
- NCT00382174: Study of Thymosin Beta 4 in Patients With Pressure Ulcers. ClinicalTrials.gov, 2026.
- NCT00311766: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa. ClinicalTrials.gov, 2026.
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences, 2010.
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine, 2021.
- Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular Research, 2025.
- NCT05485818: Phase IIa Clinical Study of Efficacy and Safety of Injectable Recombinant Human Thymosin Beta 4 in Patients With Acute Myocardial Infarction. ClinicalTrials.gov, 2026.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
- Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer’s disease. International Immunopharmacology, 2026.
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 2003.
- The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal, 2003.
- Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal, 2010.
- The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences, 2012.
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, 2024.
- Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. Journal of Proteomics, 2016.
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A, 2012.
- Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 2003.
- Effects of thymosin β4-derived peptides on migration and invasion of ovarian cancer cells. Genes & Genomics, 2021.
- Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica, 2010.
- TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis, 2023.
- Medical and surgical interventions for neurotrophic keratopathy. Cochrane Database of Systematic Reviews, 2025.
- Adjunctive Weekly Subcutaneous Thymosin β4 and BPC-157 With Intensive Rehabilitation in Subacute AIS-B Thoracic Spinal Cord Injury: A 6-Month Open-Label Controlled Pilot Study. American Journal of Medical and Clinical Research & Reviews, 2026.
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. US Food and Drug Administration, 2026.
- Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities. medRxiv (preprint, not peer-reviewed), 2026.
- Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004.
- openFDA drug adverse event (FAERS) data. US Food and Drug Administration, 2026.
